MedPath

Valganciclovir

These highlights do not include all the information needed to use VALGANCICLOVIR FOR ORAL SOLUTION safely and effectively. See full prescribing information for VALGANCICLOVIR FOR ORAL SOLUTION. VALGANCICLOVIR for oral solution Initial U.S. Approval: 2001

Approved
Approval ID

cc6c4939-7908-439c-b1b8-6b52e826c7a5

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jul 13, 2023

Manufacturers
FDA

Florida Pharmaceutical Products, LLC

DUNS: 084014259

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Valganciclovir

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code71921-210
Application NumberANDA216317
Product Classification
M
Marketing Category
C73584
G
Generic Name
Valganciclovir
Product Specifications
Route of AdministrationORAL
Effective DateJune 20, 2023
FDA Product Classification

INGREDIENTS (6)

VALGANCICLOVIRActive
Quantity: 50 mg in 1 mL
Code: GCU97FKN3R
Classification: ACTIB
MANNITOLInactive
Code: 3OWL53L36A
Classification: IACT
SODIUM BENZOATEInactive
Code: OJ245FE5EU
Classification: IACT
POVIDONE K30Inactive
Code: U725QWY32X
Classification: IACT
SUCRALOSEInactive
Code: 96K6UQ3ZD4
Classification: IACT
TARTARIC ACIDInactive
Code: W4888I119H
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Valganciclovir - FDA Drug Approval Details